Search
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Lopinavir
go.drugbank.com/drugs/DB01601ApprovedInvestigational[A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]
AX200
go.drugbank.com/drugs/DB05093InvestigationalAX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
Meropenem
go.drugbank.com/drugs/DB00760ApprovedInvestigationalIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI).
International brands: Eropescyllo-inositol
go.drugbank.com/drugs/DB03106InvestigationalAn isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. … Scyllitol has been investigated for the treatment of Alzheimer Disease.
Andrographolide
go.drugbank.com/drugs/DB05767InvestigationalThe herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.
Linerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigational[A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.